{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "α-synuclein",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "α-synuclein A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that the 20S proteasome produces C-terminal fragments from both mutant and wildtype αSyn, which accelerate fibrillization in all α-synucleins. The rate of formation of soluble oligomers correlates with the disease-associated mutations when both proteasome and liposomes are present.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links the mutations to altered amyloid formation and oligomerization rates, defining the disease mechanism through proteasome-mediated fragmentation and liposome binding."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay uses proteasome-mediated fragmentation and liposome binding, standard techniques in the field.",
          "judgment": "Yes",
          "reasoning": "The assay is applicable to the disease mechanism described, as it employs standard techniques for evaluating protein fragmentation and amyloid formation."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls (wildtype and mutant proteins) and multiple replicates are used, with the assay validated in the context of the paper's findings.",
          "judgment": "Yes",
          "reasoning": "The assay includes both wildtype and mutant controls, and multiple replicates are reported, ensuring validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports that the mutation affects oligomerization rates but does not provide OddsPath calculations.",
          "judgment": "Max PS3_supporting / Max BS3_supporting",
          "reasoning": "The data shows the mutation correlates with altered oligomer formation, but the exact OddsPath is not calculated. The total number of controls (1) is less than 11, leading to a PS3_supporting classification."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "α-synuclein",
        "Protein_Change": {
          "ref": "L",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "α-synuclein E46K"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that the mutations have different effects on amyloidogenicity and vesicle-binding activity.",
          "judgment": "Yes",
          "reasoning": "The paper describes varying effects of mutations on amyloid formation and binding, but does not explicitly link them to pathogenicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay uses proteasome-mediated fragmentation and liposome binding, standard techniques in the field.",
          "judgment": "Yes",
          "reasoning": "The assay is applicable to the disease mechanism described, as it employs standard techniques for evaluating protein fragmentation and amyloid formation."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls (wildtype and mutant proteins) and multiple replicates are used, with the assay validated in the context of the paper's findings.",
          "judgment": "Yes",
          "reasoning": "The assay includes both wildtype and mutant controls, and multiple replicates are reported, ensuring validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports that the mutation affects amyloidogenicity and vesicle-binding activity but does not provide OddsPath calculations.",
          "judgment": "Max BS3_supporting / Max BS3_moderate",
          "reasoning": "The data shows the mutation correlates with altered amyloidogenicity and binding, but the exact OddsPath is not calculated. The total number of controls (1) is less than 11, leading to a BS3_supporting classification."
        }
      ],
      "final_strength": "BS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "α-synuclein",
        "Protein_Change": {
          "ref": "L",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "α-synuclein A53T"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that the mutations have different effects on amyloidogenicity and vesicle-binding activity.",
          "judgment": "Yes",
          "reasoning": "The paper describes varying effects of mutations on amyloid formation and binding, but does not explicitly link them to pathogenicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay uses proteasome-mediated fragmentation and liposome binding, standard techniques in the field.",
          "judgment": "Yes",
          "reasoning": "The assay is applicable to the disease mechanism described, as it employs standard techniques for evaluating protein fragmentation and amyloid formation."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls (wildtype and mutant proteins) and multiple replicates are used, with the assay validated in the context of the paper's findings.",
          "judgment": "Yes",
          "reasoning": "The assay includes both wildtype and mutant controls, and multiple replicates are reported, ensuring validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports that the mutation affects amyloidogenicity and vesicle-binding activity but does not provide OddsPath calculations.",
          "judgment": "Max BS3_supporting / Max BS3_moderate",
          "reasoning": "The data shows the mutation correlates with altered amyloidogenicity and binding, but the exact OddsPath is not calculated. The total number of controls (1) is less than 11, leading to a BS3_supporting classification."
        }
      ],
      "final_strength": "BS3_supporting"
    }
  ]
}